As debate intensifies in the U.S. over abortion, a new survey finds nearly half of all women support alternatives to visiting a medical facility in order to obtain the abortion medicine to terminate pregnancies. And the findings suggest there is potential to expand access to abortion care, if regulators can be persuaded to loosen regulations governing access to the medicine, according to the researchers.
Currently, women in the U.S. must obtain mifepristone at a doctor’s office, clinic, or hospital under a risk management program required by the Food and Drug Administration. The restrictions were imposed when the drug was approved in 2000 and stipulate Mifeprex may not be sold in pharmacies and health care providers must complete a certification process.
About the Author Reprints
